Christenson ES, Ho WJ, Shu D, Durham JN, et al. Correction: Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair-Proficient Colorectal Cancer. Clin Cancer Res 2025;31:5317.
PMID: 41392646